Keywords: MorphoSys, MOR1-3, Rheumatoid arthritis, Ph Ib/IIa, Partnering opportunities

MorphoSys rises on positive mid-stage results for RA compound MOR103

Article | 24 September 2012

Print This

German biotechnology firm MorphoSys (FSE: MOR) saw its shares rise 15.1% to an 11-year high of 22.30 euros on Friday, after the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in